According to GlobalData’s medical device pipeline database, 190 Next Generation Sequencing (NGS) Tests devices are in various stages of development globally. GlobalData’s report Next Generation Sequencing (NGS) Tests provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, 127 are in active development, while the remaining 63 are in an inactive stage of development. There are 59 products in the early stages of development, and the remaining 68 are in the late stages of development.

Next generation sequencing (NGS) refers to high-throughput methods for DNA sequencing that are not Sanger-based. NGS technology has largely superseded Sanger sequencing in academic or genome research and is increasingly being applied in clinical practice. The technique is highly scalable and typically involves fragmenting the genome and then randomly sampling for and sequencing these fragments. NGS can be performed on formalin-fixed and paraffin-embedded (FFPE) and freshly collected tissue specimens and on fine-needle aspiration samples and small biopsy specimens. NGS encompasses a number of different sequencing platforms; whole-genome sequencing, exome sequencing, transcriptome sequencing (mRNA sequencing), and targeted sequencing of multigene panels, all of which simultaneously sequence millions of DNA fragments and later reply on bioinformatics analysis to map these reads to a human reference genome. In this model, GlobalData has considered pyrosequencing reagents to be NGS tests. One unit refers to one test.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Next Generation Sequencing (NGS) Tests pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Next Generation Sequencing (NGS) Tests devices. Overall, most of these Next Generation Sequencing (NGS) Tests pipeline devices are being developed by private entities.

Key players involved in the active development of Next Generation Sequencing (NGS) Tests include HaploX Biotechnology, Qiagen, Thermo Fisher Scientific, IvyGene Diagnostics, GeneCast Biotechnology, Epigenomics, Illumina, Inivata, Micronoma and Invivoscribe.

For a complete picture of the developmental pipeline for Next Generation Sequencing (NGS) Tests devices, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.